Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adherex Technologies, Inc.
Biopharmaceutical company reports loss of $0.02 per share
June 26th, 2004
Adherex Technologies, Inc., (AHX) reported its fiscal year 2004 third quarter and 9-month results for the period ending March 31, 2004. "This was an important quarter for the company as we continued our evolution to an enterprise focusing on the development of important and innovative approaches to the treatment of cancer," said William Peters, MD, PhD, MBA, chairman and CEO of Adherex. "With the completion of the $23.5 million financing in December and the recent $12.4 million "bought deal" and concurrent private placement, we have been able to devote even more energy to drug development." The company has expanded its corporate operation in Research...
Source: Law & Health Weekly (2004-06-26)
|
